AstraZeneca Opens Clinical Research Facility In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - AstraZeneca opened its first Chinese Clinical Pharmacology Unit (CPU) Sept. 4, partnering with Peking University on a facility that will focus on Phase I research of therapies targeting infections, diabetes and cardiovascular diseases
You may also be interested in...
AstraZeneca To Eliminate 1,400 Jobs In Europe Even As It Expands In China
BEIJING - AstraZeneca is expanding its main pharmaceutical manufacturing facility and logistics center in China even as the company prepares to close some smaller sites in Spain, Belgium and Sweden, according to AstraZeneca executives in the United Kingdom and China
AstraZeneca To Eliminate 1,400 Jobs In Europe Even As It Expands In China
BEIJING - AstraZeneca is expanding its main pharmaceutical manufacturing facility and logistics center in China even as the company prepares to close some smaller sites in Spain, Belgium and Sweden, according to AstraZeneca executives in the United Kingdom and China
AstraZeneca’s Head Of R&D Asia Patrick Keohane On Balancing East And West: An Interview With PharmAsia News (Part 2 of 2)
AstraZeneca's Head of R&D in Asia Patrick Keohane sat down recently with PharmAsia News' Australia bureau to talk about AstraZeneca's footprint in Asia and how the company's thinking is changing as a result of looking toward Asia.